TransMedics stock holds as Needham sees 1Q25 beat

On Wednesday, Needham maintained its Hold rating on TransMedics Group (NASDAQ:TMDX) shares, which currently trades at $70.79. According to InvestingPro data, the company has demonstrated remarkable revenue growth of 82.7% over the last twelve months, though its stock has experienced significant volatility, falling 51% in the past six months. Analysts at the firm have been closely tracking the company’s performance through a newly developed monthly report that leverages data from the Scientific Registry of Transplant Recipients (SRTR). This report is designed to forecast TransMedics’ organ transplant volumes in the United States, which appear to be highly correlated with the machine-perfused organ transplant volumes reported by SRTR.

The utilization of SRTR data has provided Needham analysts with insights that could have anticipated TransMedics’ third-quarter revenue miss in 2024 and the subsequent fourth-quarter beat. The firm intends to continue publishing these monthly reports, which will serve as a tool to estimate TransMedics’ quarterly U.S. sales.

According to the most recent SRTR data from January and February 2025, TransMedics is expected to surpass consensus sales estimates for the first quarter of 2025. Needham’s analysis suggests that TransMedics could report U.S. sales of approximately $129 million for 1Q25, which would exceed their previous estimate of $120 million. The company’s strong financial health is reflected in its impressive current ratio of 8.3 and moderate debt levels, as reported by InvestingPro.

This projection is significant as it indicates a potential upside to TransMedics’ financial performance, with the company likely to report stronger than anticipated sales figures. The SRTR data has proven to be a reliable indicator of TransMedics’ financial outcomes, offering a valuable resource for analysts and investors monitoring the company’s progress.

TransMedics Group specializes in organ transplant technology, and its financial results are closely watched by market participants interested in the healthcare and biotechnology sectors. The company’s ability to meet or exceed sales expectations can have implications for investor confidence and stock performance. Analyst price targets currently range from $80 to $125, suggesting potential upside, while InvestingPro analysis indicates the stock is fairly valued at current levels. For deeper insights, investors can access TransMedics’ comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks, which includes detailed financial health scores and additional ProTips.

In other recent news, TransMedics Group Inc . reported strong financial results for the fourth quarter of 2024, surpassing expectations with earnings per share of $0.19 compared to the forecasted $0.16. The company also reported revenue of $121.6 million, exceeding the anticipated $109.5 million, marking a 49.8% increase year-over-year. For the full year, TransMedics’ revenue surged by 82.7% to $441.5 million, with the U.S. market contributing significantly with a 91% increase to $422 million. This performance was bolstered by the company’s first year of positive operating cash flow, totaling $48.8 million, and a net profit of $35.5 million.

TransMedics’ market share in the U.S. for organ care systems grew to 20.9%, highlighting its expanding influence in the sector. The company has set a revenue guidance of $530 million to $552 million for 2025, projecting growth of 20-25%. Additionally, TransMedics plans to continue investing in its next-generation OCS technology platform to further enhance its market position. The company also addressed concerns from a recent short seller report, confirming that an independent investigation found no evidence of fraud or misconduct.

These developments underscore TransMedics’ strong financial health and strategic growth initiatives in the organ care systems market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.